Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View

Michele Miraglia Del Giudice, Amelia Licari, Ilaria Brambilla, Maria Angela Tosca, Giorgio Ciprandi

Research output: Contribution to journalArticlepeer-review


To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations. The present review provides a pragmatic summary of the clinical indications of AIT in pediatric asthma, including the immunological mechanisms, the predictive biomarkers, and the safety issues in clinical practice.
Original languageEnglish
JournalChildren (Basel, Switzerland)
Issue number6
Publication statusPublished - Jun 8 2020


  • allergen-specific immunotherapy
  • allergic asthma
  • children
  • subcutaneous immunotherapy
  • sublingual immunotherapy


Dive into the research topics of 'Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View'. Together they form a unique fingerprint.

Cite this